AZTherapies
2011
FOUNDED
PRIVATE
STATUS
11-20
EMPLOYEES
Later Stage VC
LATEST DEAL TYPE
$19M
LATEST DEAL AMOUNT
2
INVESTORS
Description
Developer of pharmaceutical drugs designed to provide treatment for multiple neurodegeneration and neuroinflammation-related CNS diseases. The company's products include ALZT-OP1 is a novel multi-action combination drug regimen which is use to modify disease progression by slowing down or halting Alzheimer's disease early in its development, enabling healthcare providers to cure Alzheimer's patients.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
- 200 Clarendon Street
- 17th Floor
- Boston, MA 02116
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore AZTherapies’s full profile, request a free trial.
AZTherapies Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 12-Jul-2019 | $19M | 000.00 | Completed | Generating Revenue | |
| 4. Later Stage VC (Series B) | 16-Oct-2018 | 000.00 | 000.00 | 00000 | Completed | Generating Revenue |
| 3. Later Stage VC | 0000 | 000.00 | Completed | Generating Revenue | ||
| 2. Later Stage VC (Series A) | 06-Feb-2017 | $16.4M | $26.4M | 00000 | Completed | Generating Revenue |
| 1. Early Stage VC | 06-Jan-2015 | $10M | $10M | Completed | Generating Revenue |
AZTherapies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| Series A-2 | 0,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 00.0 | 0.000 | |
| Series A-1 | 2,084,052 | $0.000100 | $3.33 | $3.33 | 1x | $3.33 | 4.58% | |
| Series A | 4,212,559 | $0.000100 | $4 | $4 | 1x | $4 | 9.26% |
AZTherapies Competitors (39)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cadent Therapeutics | Venture Capital-Backed | Cambridge, MA | 0 | 000.00 | 00000000000 | 000.00 |
| 0000 | Venture Capital-Backed | San Diego, CA | 00 | 00.000 | 00000 00000 | |
| 000000000 00000000 | Venture Capital-Backed | Cambridge, MA | 00 | 000.00 | 0&0 | |
| 000000 00000000000 | Venture Capital-Backed | San Diego, CA | 000.00 | 00000000000 | 000.00 | |
| 00000000 000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 000.00 | 0000000000 0 | 000.00 |
AZTherapies Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| DRADS Holdings | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Dolby Family Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
AZTherapies Executive Team (8)
1 Former Executive
You’re viewing 5 of 8 executives. Get the full list »AZTherapies Board Members (8)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| David Elmaleh Ph.D | AZTherapies | Founder, Chairman & Chief Executive Officer | 000 0000 | |
| David Taft | Self | Board Member | 000 0000 | |
| George Behrakis | AZTherapies | Board Member | 000 0000 | |
| Gillian Sandler | Self | Board Member | 000 0000 | |
| John Porter | AZTherapies | Board Member | 000 0000 |